In the last couple of years, we have seen interest in psychedelic treatments increase significantly as more studies unearth the benefit of the substances, particularly for mental-health conditions. Randomized controlled trials have found that psychedelics such as LSD, psilocybin, and ayahuasca may offer considerable relief from symptoms of depression.
While trials have proven the drugs’ effectiveness in treating mental-health conditions, the mechanisms by which these substances work as well as their actual effectiveness remains unknown.
This is a significant concern in this field, especially since conducting successful blind clinical trials is rather difficult. Blinding is necessary in trials because it ensures that neither the researchers nor participants know who is receiving the placebo or active drug. The distinctive and potent effects of psychedelics make it easy for participants in trials to guess if they’re part of the control group or in the treatment group.
A recently conducted analysis has determined that the effectiveness of psychedelics may have been overestimated. The systematic review and meta-analysis were carried out by investigators in Taiwan, whose objective was to evaluate the acceptability and true comparative effectiveness of psychedelics in comparison to conventional antidepressants. For their analysis, the investigators centered on the effectiveness of psilocybin, MDMA and LSD as compared to escitalopram, a commonly prescribed antidepressant.
The researchers sifted through various databases, including the Cochrane Central Register of Controlled Trials and Medline, to find relevant studies. Included in the analysis were studies that had randomized controlled trials with patients with depressive symptoms related to life-threatening conditions or clinically diagnosed depression. The studies also had to compare oral monotherapy treatments.
Once this was done, the researchers separated responses from antidepressant trials from those in placebo trials to offer an accurate estimate of the true effectiveness of these drugs.
They determined that only psilocybin administered in high doses demonstrated greater effectiveness in comparison to the placebo. This suggests that while psychedelics do hold promise, their effectiveness in comparison with standard antidepressants may have been overestimated in prior trials because of things such as unsuccessful blinding in trials.
The study had some limitations, including the focus on short-term effects of psychedelics. The analysis didn’t evaluate the long-term efficacy of psychedelics as compared to antidepressants. Understanding how these therapies work over the long-term is important because depression is a chronic illness.
Another limitation was the small number of studies included in the analysis. Future studies should center on bigger, longer-term studies that include strict blinding techniques to ensure that the true efficacy of psychedelics can be evaluated accurately.
The analysis’ findings were reported in the “BMJ.”
For companies that have multiple psychedelic drug-development programs underway, such as atai Life Sciences N.V. (NASDAQ: ATAI), it is increasingly crucial that accurate data on the efficacy of their formulations is collected so that regulators rely on that data to make decisions about different drug applications.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
A cannabis producer behind one of a handful of farmgate stores in New Brunswick is closing its doors as it looks to reset its cannabis business from the ground up.
Crystal Cure Inc., a micro cannabis producer in Shediac Cape, New Brunswick, says it will cease its cannabis operations at the end of September, primarily due to delays in securing the financing needed for its planned expansion.
The company’s CEO, Jonathan Wilson, says this is likely not the end of the road for the company but a chance for them to reset their business, building out a new facility that better matches their needs and the realities of market demands.
“Eventually we knew that we were going to have to make a decision,” Wilson tells StratCann.
“We made this decision now before it gets to a point where we can’t meet commitments as we’ve seen happen to others. We are optimistic that this is not goodbye to the legal cannabis industry, but hopefully more of a see-you-soon.”
The company has been operating for several years inside a much larger facility that has remained underutilized. In late 2023, Crystal Cure made the decision to downgrade their licence from a standard to a micro, reflecting that it was already operating with a very small footprint.
The building the company has been operating is 63,000 sq. ft., built at a time when the company was looking at bold early market projections. However, due to this and problems with how the facility was constructed, Crystal Cure wasn’t able to fully utilize the space. Since 2019, the company has also been involved in legal proceedings concerning the construction of its original facility.
“We are still operating out of a tiny, temporary space that was only supposed to be in place for a year,” notes Wilson in a company press release. “However, the construction of our original facility was halted prematurely when the structure was rendered unusable, which now has to be dealt with in a court of law. This has added a lot of costs to a small operation, and also takes away our focus, time, and energy from what matters.”
Wilson adds, “When you combine the added pressure with the current financial ecosystem of the legal cannabis industry, it doesn’t give us enough to be able to survive, let alone generate enough profit from our operations to expand to meet demand. This is one example of the impacts of the short-sighted decisions made by policymakers across the country, impacts that they’ve flat out ignored at both the federal and provincial levels.”
Although the owners had hoped to maintain their current licence while they bring in new investors to build out a new purpose-built facility, Wilson says they had to finally make the tough decision to revoke their licence and shut down operations while they work towards that ultimate goal.
“We love the legal cannabis industry and we believe we will play a part in its future here in Canada,” he explains in a company press release. “However, as ironic as it is, we have to take a step back from it and focus elsewhere in order for us to survive long enough to secure the funding for our expansion. We have found a potential partner that believes in us and understands our vision. We will do whatever is necessary to hang on, even if it means ceasing our current operation and starting again. We are in this for the long-term.”
One thing that had kept the company going over the past year, giving them hope they could hold off this new decision to shut down entirely, was the success of their cannabis farmgate store, Le Backdoor, one of just six in New Brunswick and only a few more in all of Canada.
That’s the part I’m the saddest about,” Wilson tells StratCan. “The supporters of farmgate are the ones who have given us an extra couple of months. This summer has been incredible with new customers and tourists, and the feedback we get has helped let us know we are doing something right. It helped us go a little longer.”
“The part I’m going to miss the most is seeing customers every day.”
In the meantime, Crystal Cure will continue to have a foothold in the cannabis industry through its sister company, Gourmet Chef Packers, which sells living soil, worm castings and other agricultural inputs under the brand Adonis Growing Solutions. Clients include several other licensed cannabis producers.
“We have been working behind the scenes on a project across the parking lot, so to speak, focused on regenerative agriculture and many of the things we hold near and dear.” Wilson adds. “This will allow us to still stay connected to the industry we are so passionate about, while at the same time, being able to work in an exciting environment without the exorbitant excise taxes, fees, and over-regulation that have plagued producers from day one.”
“We managed to survive an additional year longer than we thought, but unfortunately it wasn’t long enough. We made this decision now before it gets to a point where we can’t meet commitments as we’ve seen happen to others. We are optimistic that this is not goodbye to the legal cannabis industry, but hopefully more of a see-you-soon.”
According to Wilson, consumers of Crystal Cures products will have a few more weeks of availability before their limited releases are no longer available.
Quebec-based cannabis producer Culture Kizos Inc./Kizos Culture Inc. recalled one lot of its Coterie Double Infused Sour Apple Blunt Pre-rolls cannabis extract earlier this month.
On August 19, Health Canada listed a voluntary product recall for the one-gram pre-rolls due to microbial contamination for Lot L24135H packaged on May 14, 2025. This product was sold through authorized retailers in Alberta.
Health Canada says the affected product does not meet certain microbial contaminant limits for bacteria as specified by the Good Production Practices requirements of the Cannabis Regulations. However, the probability of serious adverse health consequences is remote, adds the recall notice.
As of August 19, Culture Kizos Inc./Kizos Culture Inc. and Health Canada say they have not received any complaints related to the recalled lot. Neither Culture Kizos Inc./Kizos Culture Inc. nor Health Canada have received any adverse reaction reports for the recalled cannabis product lot.
There were 1,281 units of recalled product sold from June 9 to August 12, 2024.
Tokyo Smoke says it will be closing 29 of its stores as it seeks creditor protection.
The cannabis retailer says the closures are part of a restructuring process the brand is seeking out under the Companies’ Creditors Arrangement Act (CCAA) from the Ontario Superior Court of Justice.
The company says other locations across Ontario, Manitoba, Saskatchewan, and Newfoundland and Labrador will remain in operation, at least for the time being.
The company says it has secured financing to continue operating while it restructures its business.
In a press release, Tokyo Smoke says that, following a thorough review of all available options and alternatives, the company has now begun this restructuring to better align its operations with current market and regulatory conditions, which it says have significantly changed since the retail chain launched.
Reconstruct LLP is acting as legal advisor to Tokyo Smoke, and Alvarez & Marsal Canada Inc. is acting as the CCAA Monitor.
Tokyo Smoke’s restructuring plan focusses on closing “underperforming locations”, while also beginning discussions with landlords to obtain consensual lease amendments for its remaining store locations. The company lists 61 corporate stores, 29 franchise stores, and 11 vacant stores for a total of 101 in the monitor report, as well as 474 employees. Five of its corporate stores, comprising 37 employees, are unionized.
Tokyo Smoke says the “significant overhead costs” required to manage its approximately 100 retail locations have resulted in material and recurring losses. For the 12-month period ended June 30, 2024, the retail chain generated revenue of approximately $93.5 million and EBITDA of negative $10.5 million.
The book value of Tokyo Smoke’s liabilities exceeds the book value of its assets by approximately $89.1 million. As at June 30, 2024, the company held assets with a book value of approximately $148.2 million and had liabilities with a book value of approximately $237.4 million. Tokyo Smoke had a net loss of $29.3 million for the fiscal year that ended June 30, 2024.
The motion for ther initial order was approved on August 27. The comeback hearing will be held on Friday, September 6, 2024 8:30 a.m. by Zoom.
Americans’ perceptions of cannabis’ effects have become less optimistic over the last two years; a slight majority now worry that most users (51%) and society as a whole are harmed by it. This is a significant change from 2022, when opinions were more evenly divided and more people (53%) thought marijuana had a good impact on users, while only 45% thought it had a negative one.
These new insights are based on a Gallup Consumption Habits survey conducted from July 1 to July 21, 2024, which shows that a sizable portion of different demographics still have favorable opinions of marijuana. This group comprises those who have personally experimented with marijuana, Democrats, young people aged 18 to 34 years of age, and those who seldom or never attend religious events.
Those who have never tried cannabis, Republicans, those who attend religious services regularly, and those who are 55 years of age or older, on the other hand, have different opinions and generally believe that most cannabis users have been negatively impacted. Notably, opinions are more divided among independents and people aged between 35 and 54 years old.
A pattern that is evident in all of these groups is a decline in the perception of cannabis’ beneficial effects as compared to prior years. Furthermore, fewer than one-half of respondents in each of these categories now believe that cannabis has a beneficial impact on society.
In a different section of the poll, Gallup asked respondents to rank the level of danger associated with chewing tobacco, cigarettes, e-cigarettes, pipes, cigars, nicotine patches, cannabis and alcohol.
While all eight narcotics are viewed as “somewhat” or “very” hazardous by most Americans, marijuana is the least of the lot. The majority of respondents — roughly two-thirds — believe that marijuana is either extremely (26%) or moderately (40%) dangerous. This pales in comparison to the broad consensus that products such as e-cigarettes, cigarettes and chewing tobacco are harmful; more than 90% of American people consider these to be dangerous, with the majority believing they are extremely problematic.
Public sentiment on the dangers of cannabis has shifted slightly since 2023, with the percentage of those who see it as very harmful rising from 23% to 26%, and those considering it somewhat harmful shifting from 35% to 40%.
In addition, 13% of American adults today report smoking cannabis, a small decrease from the 17% noted in 2023, whereas 12% of individuals use edibles. In addition, 7% of American adults prefer e-cigarettes or vaping, and 58% of individuals say they drink alcohol, making it the most commonly taken drug.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Greenway Greenhouse Cannabis Corporation reported net revenue of nearly $2.4 million in the first quarter of 2025 ended June 30, 2024, and a $541,478 loss after operating expenses.
The Ontario cannabis producer, which sells under its EPIC Cannabis Co. and MillRite, as well as the B2B wholesale market, saw a 104% increase in net revenue compared to the same period in 2023, along with a 94% increase in grams or grams equivalent sold compared to Q2 2023. This is the second reporting period Greenway has included sales of its branded products.
Greenway’s losses were also down significantly from the same period in the previous year and the previous quarter.
“We are thrilled to announce a record-breaking quarter, achieving a record net revenue, EBITDA, and achiev[ing] a positive net cash flow provided by operating activities,” said Jamie D’Alimonte, CEO of Greenway.
“This performance reflects our focus and commitment to producing quality cannabis, and finding the best partners and pathways to bring it to consumers. We achieved this while still keeping our cost of production low, and our yields high. This combination is what we believe separates us from other public cannabis companies in Canada.”
The company also recently received CUMS-GAP and GACP certifications for the purpose of international sales. Subsequently, Greenway says it has now harvested its first crop, intended for export.
Greenways expected an average yield per plant of 125 grams in 2024, down from 170 grams in 2023, with the estimated selling price of dried flower staying level at $1.10 per gram. The post-harvest cost to complete and sell that gram of cannabis increased from $0.45 in 2023 to $0.45 in 2024.
Greenway’s EPIC Berry Sunset products became available for purchase in Ontario in this most recent quarter. Greenway operates a cannabis nursery facility in Kingsville, Ontario, and a flowering and processing facility in Leamington, Ontario. It is a majority-owned subsidiary of Sunrite Greenhouses Ltd.
As of June 30, 2024, Greenway reports a working capital deficiency of $940,130 and an accumulated deficit of $18,294,141. The company says it has insufficient cash to pay creditors for its current working capital obligations and operations for the next twelve months. Its ability to continue as a going concern depends on its ability to get sufficient additional funding and generate enough revenues and positive cash flows from its operating activities to meet its obligations and fund its planned investments and operations.
Officials in New Brunswick have confirmed they once again seized products from an unlicensed store selling unregulated cannabis, vapes, tobacco, and psilocybin products.
On August 15, peace officers from New Brunswick’s Department of Justice and Public Safety, with assistance from RCMP, again executed a search warrant at the L’Nuk Trading Post at 575 Main St., Moncton and at 767 Coverdale Rd., Riverview.
The Riverview store was raided on August 2, arresting two and seizing products. The store later posted on social media that enforcement officers had executed a raid on the Moncton location on August 15. This new report confirms those subsequent raids.
Both stores have since reopened. The Moncton store also faced enforcement action in August 2023, when officers seized 7,719.5 grams of dried cannabis, 690.4 grams of hashish, 171.3 grams of psilocybin (magic mushrooms), 246 grams of cannabis shatter, an undisclosed quantity of assorted cannabis products, edibles, contraband cigarettes, and $10,432 in cash.
The store quickly reopened following that raid. The social media accounts describe the business as Indigenous-owned and indicate they “don’t sell products, we share our tradition.”
In the most recent raids on August 15, a 49-year-old male and a 23-year-old female employee were arrested and released on an undertaking. They face charges under the Cannabis Control Act, the Tobacco Tax Act, and the Controlled Drugs and Substances Act. The investigation is ongoing.
Items seized include:
$45,878 in cash
5.5 kilograms of cannabis bud
1.5 kilograms of hashish
1,811 cannabis joints
470 packs of live resin and shatter
1,368 edible cannabis products
436 THC vape products
150 THC oil products
87 THC products
seven psilocybin products (mushrooms)
36,020 contraband cigarettes
101 flavoured cigars
122 flavoured vape products
31 flavoured nicotine pouches
At the Riverview location, two employees were arrested: a 21-year-old woman and a 31-year-old woman. Both were released on an undertaking and are scheduled to appear in court on November 4. They face charges under the Cannabis Act and the Tobacco Tax Act.
Seized items include:
23.3 kilograms of dry cannabis
3,397 cannabis joints
73,400 unstamped cigarettes
$5,111.60 in cash
99 cannabis vapes
176 cannabis edibles
375 cannabis byproducts
15 flavoured nicotine pouches
155 flavoured cigars
187.6 grams of hashish
New rules in New Brunswick, passed earlier this year, now mean that landlords can face fines of up to $5,000 a day for failing to prohibit the sale of illegal cannabis using their property.
(Globe Newswire) Toronto – Cronos Group Inc. is expanding its portfolio for its Lord Jones® brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones® Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada.
Since the brand’s launch in Canada in November 2023, Ice Water Hash Fusions Pre-Rolls have become the best-selling hash-infused pre-rolls in the country1. Curated with flower and terpene-rich ice water hash and fitted with a branded ceramic tip designed to cool the smoke, these 1g pre-rolls provide an elevated experience. The brand’s live resin vapes are designed to deliver a premium and highly potent vape experience at 70%+ THC in each all-in-one device and 510-cartridge. As of July 2024, the Lord Jones® brand has become the third best-selling live resin vape brand in Canada1.
The Lord Jones® Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes:
Lord Jones® Ice Water Hash Fusions Pre-Rolls:
Sour Blueberry x Sour Blueberry
1g ice water hash flower pre-roll with blueberry and gas flavor notes.
Indica | THC: 35-41% | 1x1g
Snow Lotus x Animal Mints
1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes.
Hybrid | THC: 35-41% | 1x1g
Lord Jones® Live Resin Vapes (All-in-One and 510-Cartridge):
Gorilla Z Live Resin Vape
A flavor-forward vape designed to boast an elevated berry, cherry, and grape flavor experience.
Hybrid | 70+% THC
Available in two hardware options that are optimized for live resin usage:
A sleek 0.5g all-in-one device
A high-quality 1g 510-thread cartridge
“These new additions to our growing portfolio of Lord Jones®innovations demonstrate our commitment to delivering exceptional and truly differentiated products to the Canadian market,” said Mike Gorenstein, Chairman, President and CEO, Cronos. “We are thrilled by the enthusiastic response to the Lord Jones® brand after nearly one year in Canada, and we’re excited to launch future innovations that will introduce adult consumers to new and unique ways to experience and enjoy cannabis.”
So far, 2024 has been a year of challenges as LPs and retailers grapple with shifting consumer preferences and a demonstrated lack of brand loyalty.
While a rising tide lifts all ships, this year has brought sales decline and a slowing of consumers transitioning to the legal market. While many industry participants are hoping for revised regulations or excise tax reforms to provide much needed relief, the battle wages on as LPs compete for market share and most elusively, consumer mindshare.
For the three months ended June 30, 2024, Decibel Cannabis reported net revenue of $22.16 million and a net income of $122,000. Notably, the company has achieved $1.8 million in cashflow from operations and $1.2 million in free cash flow for the six months ended June 30,2024.
During good times, companies should be investing into their balance sheet, optimizing to improve margins, and developing battle tested processes to build a protective moat in advance of the hard times.
During challenging economic times, companies need to be able to pivot, operate on constrained budgets and make important strategic decisions.
Statistics Canada released June 2024 retail cannabis sales, with sales at a national level continuing to fall from May levels, reaching $402 million, down 2.8 per cent. The June sales are also down 8.2 per cent, year over year.
In 2024, numerous LPs have encountered cashflow, liquidity and solvency issues. Seeking relief under the Companies’ Creditors Arrangement Act (CCAA), LPs are able to restructure or sell their companies in a supervised manner.
Decibel Cannabis is delivering results and adapting in an evolving market. Refocusing on their core brands, Decibel is optimizing their SKU portfolio, improving internal operations and targeting corporate savings.
“Decibel has shown good discipline reducing our current liabilities by ~5mm this quarter. Market share has been challenged but early indications from Qwest relaunch suggest we will regain market share in flower. A continued focus on execution and capital efficiency will serve as the platform for future growth.” said Benjamin Sze, Decibel’s chief executive officer, in a company issued press release.
Sales and market share
For the six months ended June 30,2024, Decibel posted net revenue of $43 million, down $10 million or 20 per cent compared to 2023. The decline is driven by a $9 million decrease in Canadian recreational sales and $1.3 million decrease in international sales. Possessing a 5.6 per cent national market share in Q2 2024, Decibel Cannabis has the fourth largest market share of LPs in the Canadian recreational market.
The decline in international sales is the result of Decibel changing distribution partners in Israel and halting exports to the market. The company has announced they are now shipping vapes to Australia and received authorization to sell vapes and flower in the UK market in early Q3 2024.
QWEST relaunch
As an early market leader, QWEST has lost market share and under indexes in the dried flower category. Refocusing on the dried flower consumer, QWEST will be relaunching with a renewed value proposition and product offerings for the Canadian market.
“QWEST started off as a premium brand. As our product mix shifted to RTC, we failed to deliver on consumer expectations in the dried flower category, while the market evolved around us. The upcoming relaunch of QWEST is focused on delivery of exceptional value to the flower consumer. This platform, once established in Canada, will give us optionality both domestically and internationally and is expected to show market share gains,” said CMO Warren Matzelle.
Discontinuation of retail operations
On April 10, 2024, Decibel completed the sale of Prairie Records. Comprised of three stores in Saskatchewan and three stores in Alberta, Fire and Flower Inc, a subsidiary of FIKA, takes over the retail assets and operations.
The company received $3 million for the sale, while realizing a $3.3 million impairment loss.
Competition and consumer preferences
Decibel noted increased competition in the infused pre-roll category, and tracked vape consumers migrating to larger formats and disposable vapes. With consumer preferences evolving, understanding their needs and getting ahead of the demand through innovation and planning is crucial.
Competition is fierce, with Jeeter entering the Canadian market and competing head on in the infused pre-roll segment.
Rightsizing and ready
With capital expenditures paused, Decibel is focused on revenue generating activities and producing savings of $2 million annually in general and administrative costs. Carrying $40.9 million in commercial mortgage loans, Decibel is shoring up their balance sheet and managing debt and liquidity level to best serve the company.
“With all the implementation, we expect to materially strengthen our balance sheet, positioning the company better to capitalize on opportunities in the future,” said CFO Stuart Boucher.
Decibel has a track record of delivering positive net income, but has struggled in the previous six months. With the Company stock continuing to languish, shareholders will be waiting and watching for Decibel Cannabis to return to its winning ways.
Endometriosis is a chronic illness that causes tissue similar to the uterine lining to grow on other organs in the body. This condition can cause severe pain in patients, particularly during periods, sexual intercourse and bowel movements. The inflammatory illness affects about 190 million girls and women of reproductive age around the globe. It has no known cure, with treatment focusing on managing its symptoms.
Now, new research has found that cannabis may help women manage symptoms of endometriosis. For the new study, researchers conducted an analysis of survey responses from 912 adult patients suffering from endometriosis in Switzerland, Austria and Germany. Of these patients, 114 of them admitted to using cannabis to manage the illness, which is known to cause a lot of pain.
The researchers found that most users of marijuana saw improvements in pain and other symptoms. In detail, about 90% saw improvements in their menstrual pain while 91% saw their sleep improve. Additionally, roughly 90% of the respondents reported that cannabis use led to a reduction in their intake of pain meds.
The researchers found that marijuana users were more likely to have tried different pain drugs in the past. Generally, the findings suggested that patients who had used cannabis also experienced serious pain and perceived pain meds to be less effective.
It should be noted that while some respondents did report more fatigue associated with the use of cannabis, side effects were otherwise minimal.
In their report, the researchers explained that women who used marijuana found it to be effective in decreasing symptom intensity. They also found that on average, respondents took roughly nine years to get diagnosed with the condition. This highlights a need for any knowledge gaps associated with endometriosis be filled while also improving access to quality healthcare.
Despite these positive findings, more studies are needed to determine dosage, the best route of administration, CBD/THC ratio, long-term effects of marijuana use and possible side effects.
The study was carried out by a four-person team from the Center of Oncological Surgery’s gynecology department at the Endometriosis Research Center Charité. The researchers included Sylvia Mechsner, Jalid Sehouli, Renata Voltolini Velho and Victoria Jasinski.
In their conclusion, the researchers noted that at the time of their research, the consumption of marijuana was still illegal in Austria, Germany and Switzerland. Medical marijuana in these countries is rarely prescribed due to complicated requirements.
As more studies are conducted on the potential benefits of using marijuana therapeutically, it is likely that more applications for this substance in managing or treating various ailments could emerge, and the mushrooming of entities that manufacture medical cannabis products, such as TerrAscend Cannabis Corp. (TSX: TSND) (OTCQX: TSNDF), will be further justified.
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Recent Comments